Chemotherapy for Advanced Thymic Carcinoma

Koizumi, Tomonori; Takabayashi, Yasuki; Yamagishi, Satoshi; Tsushima, Kenji; Takamizawa, Akemi; Tsukadaira, Akihiro; Yamamoto, Hiroshi; Yamazaki, Yoshitaka; Yamaguchi, Shinjiro; Fujimoto, Keisaku; Kubo, Keishi; Hirose, Yoshiki; Hirayama, Jirou; Saegusa, Hisanori

doi:10.1097/00000421-200206000-00012

Cited by 79 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of chemotherapy in treating this malignancy remains controversial, whereas the majority of platinum-based chemotherapy regimens have now been accepted. Recent reports demonstrated a high response rate with combination chemotherapies involving CDDP, ADR, VCR and CPA (ADOC) [9], and CDDP, VCR, ADR and VP-16 (CODE) [10] in Japanese patients with advanced TC. However, these regimens including CPA, ADR and VCR were not effective in this study.…”

Section: Discussionmentioning

confidence: 99%

Persistent and Aggressive Treatment for Thymic Carcinoma

Maruyama¹,

Suemitsu²,

Okamoto³

et al. 2006

Oncology

View full text Add to dashboard Cite

Objectives: The aim of this study is to retrospectively evaluate the role of several therapies, mainly chemotherapy, for thymic carcinoma (TC). Methods: From July 1973 to July 2005, 25 patients (15 males and 10 females) with histologically proven TC were treated at our department. The median age of the patients was 59 years, with a range of from 30 to 78 years. According to Masaoka’s staging system, there was 1 stage I patient, 3 stage II, 7 stage III, 6 stage IVa, and 8 stage IVb patients. The histological subtype was in all cases squamous cell carcinoma, nonkeratinizing type. Results: There were 6 complete surgical resections, 1 incomplete resection followed by chemoradiotherapy, 6 with radiotherapy alone, 3 with radiotherapy plus chemotherapy, and 9 with chemotherapy alone as the initial treatment. Eighteen patients were administered second-line therapy. The regimen obtaining the best response rate was doublet chemotherapy consisting of carboplatin (CBDCA) and paclitaxel. The median survival time and survival rate at 5 years for the patients excluding surgical cases with stage I/II disease were 32 months and 31%, respectively. Conclusion: The doublet of CBDCA and paclitaxel thus appears to be a promising regimen for TC and further investigation in a multi-institutional phase II trial is, therefore, strongly called for.

show abstract

Section: Discussionmentioning

confidence: 99%

Persistent and Aggressive Treatment for Thymic Carcinoma

Maruyama¹,

Suemitsu²,

Okamoto³

et al. 2006

Oncology

View full text Add to dashboard Cite

show abstract

“…Surgical treatment has been chosen against patients with early disease, but patients with recurrent advanced TC are treated with several consensus chemotherapeutic regimens, including cisplatin-based chemotherapy in the first-line setting [1]. In refractory TC, the treatment options as second- or third-line chemotherapy are limited because of poor evidence regarding effective therapeutics.…”

Section: Introductionmentioning

confidence: 99%

Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer

et al. 2014

View full text Add to dashboard Cite

Thymic cancer (TC) is a rare malignancy in thoracic tumors, and there has been no standard therapeutics for advanced or relapsed patients. The clinical significance of second-line or beyond chemotherapy for platinum refractory advanced TC remains unclear. Here, we present the experience of a patient with TC showing a complete response to S-1 as third-line chemotherapy. A 54-year-old female with TC was treated with carboplatin plus paclitaxel and thoracic radiotherapy as first-line chemoradiotherapy and amrubicin as second-line chemotherapy. After 3 cycles of amrubicin administration, the metastatic hepatic lesions revealed a markedly progressive disease. A single agent of S-1 was administered as sequencing chemotherapy. After 2 cycles of S-1, the patient achieved a complete remission of multiple metastatic sites. There was evidence of immunohistochemical staining of a low thymidylate synthase (TS) expression. The expression of TS may be closely associated with the efficacy of S-1 in patients with TC.

show abstract

“…Thymic carcinoma is a thymic epithelial neoplasm with cytological malignant features and a clinical course that tends to be much more aggressive than that of thymoma [1][2][3][4][5]. Thymic carcinoma also tends to metastasize widely, which leads to a high rate of patient mortality [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

“…Thymic carcinoma also tends to metastasize widely, which leads to a high rate of patient mortality [1][2][3][4][5]. Thus, systemic chemotherapy may be important in the treatment of thymic carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases

et al. 2009

Self Cite

View full text Add to dashboard Cite

It has been reported that cisplatin-based chemotherapy shows beneficial effects in certain patients with advanced thymic carcinoma. However, the usefulness of salvage therapy has not been reported. We focused on a new anthracycline agent, amrubicin, combined with platinum compounds as salvage chemotherapy in patients with thymic carcinoma. Six cases of unresectable and locally advanced thymic carcinoma relapsed from prior cisplatin-containing chemotherapy were treated with amrubicin (30-40 mg/m(2) day 1-3) plus platinum compounds (cisplatin 60 mg/m(2) day 1 or nedaplatin 70 mg/m(2) day 1) chemotherapy as salvage chemotherapy. Two patients showed a partial response. However, Grade 3/4 neutropenia and thrombocytopenia occurred in all and two of the patients, respectively. We conclude that thymic carcinoma is sensitive to platinum-based chemotherapy and that amrubicin appears to have significant activity against thymic carcinoma. The major toxicity is hematological toxicities.

show abstract

Chemotherapy for Advanced Thymic Carcinoma

Cited by 79 publications

References 16 publications

Persistent and Aggressive Treatment for Thymic Carcinoma

Persistent and Aggressive Treatment for Thymic Carcinoma

Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer

Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases

Contact Info

Product

Resources

About